The early stage of COVID-19 pandemic: Gastrointestinal manifestations and liver injury in COVID-19 patients in Wuhan, China

Dafan Chen1,2†, Min Ning2†, Yun Feng1 and Jun Liu3∗

1Department of Gastroenterology, Shanghai Jiao Tong University School of Medicine, Shanghai, China; 2Digestive Endoscopic Center, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China; 3Department of Nephrology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

There are few and inconsistent data focusing on gastrointestinal (GI) manifestations and liver injury in China’s early stage of COVID-19 pandemic. In this study, we research the prevalence and role of GI symptoms and liver injury in COVID-19 patients in Wuhan during the disease’s first outbreak. We conducted a cross-sectional observational study in a non-ICU unit in Wuhan, China. COVID-19 patients were consecutively admitted from 23 February 2020 to 5 April 2020. Demographic and clinical data were retrieved and analyzed throughout the disease course. A total of 93 patients were enrolled, including 45.2% moderate, 54.8% severe, and 2.2% critical type patients. 69.9% of patients had at least one GI symptom; if excluding hyporexia/anorexia, 49.5% of patients showed at least one GI symptom. The incidence rate of hyporexia/anorexia, diarrhea, nausea/vomiting, abdominal discomfort/pain, and elevated liver enzymes were 67.7, 29.0, 28.0, 21.5, and 23.7%, respectively. Patients with GI symptoms or elevated liver enzymes have a higher risk of severe type disease than patients without GI symptoms or elevated liver enzymes (67.7 vs. 25.0%, p < 0.001; 77.3 vs. 47.9%, p = 0.016, respectively), and experienced longer disease duration. In multivariate analysis, hyporexia/anorexia was confirmed as an independent predictive factor of severe type disease (odds ratio: 5.912, 95% confidence interval: 2.247–15.559; p < 0.001). In conclusion, in the early stage of the COVID-19 pandemic, GI symptoms and elevated liver enzymes are common throughout the disease course, and associated with severer disease and longer disease duration.

KEYWORDS
COVID-19, gastrointestinal symptoms, liver injury, Wuhan, early stage
Introduction

The coronavirus-associated disease 2019 (COVID-19) first broke out in Wuhan, China, in December 2019 and has spread worldwide. The pathogen responsible for COVID-19 was identified as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (1). The common symptoms of COVID-19 include fever, cough, shortness of breath and other respiratory symptoms (2). Many studies have shown that some COVID-19 patients also had gastrointestinal (GI) manifestations and liver injury, including hyporexia/anorexia, nausea, vomiting, diarrhea, abdominal discomfort, elevated liver enzymes and so on (3–6).

However, there are inconsistent data of GI manifestations and liver injury in COVID-19, especially in China’s early stage of COVID-19 pandemic. Limited studies in the early COVID-19 pandemic about the prevalence of GI manifestations and liver injury varied greatly (2, 7–9). Most of the studies were retrospective, and reported the GI symptoms and liver enzymes only at admission, but not throughout the disease course of COVID-19. Moreover, many studies investigated various clinical characteristics of COVID-19, and clinicians may not pay much attention to the GI manifestations and liver injury. So, the prevalence of GI symptoms and liver injury may be underestimated. The relationship between GI symptoms and disease severity was inconsistent. During the early COVID-19 pandemic, several studies focusing on GI symptoms showed that COVID-19 with GI symptoms had a higher risk of severe illness and intensive care unit (ICU) admission in China (8, 10). However, other studies found that patients with GI symptoms were not severer (4, 11, 12). Studies also showed that COVID-19 could have hepatic involvement, usually characterized by elevated liver enzymes though jaundice was uncommon (5, 13). Although some reports suggested that COVID-19 patients with elevated liver enzymes may have severer disease course, the result in other studies was inconsistent (5, 14, 15).

Investigating the situation of GI manifestations and liver injury in the early stage of the COVID-19 pandemic is helpful to know the change in disease characteristics with time, the impact of virus mutation on the disease development, and the measures for improving the COVID-19 course. In this study, we carried out a cross-sectional observational study, and focused on GI symptoms and liver injury throughout the disease course of COVID-19 in a non-ICU referral unit in Wuhan, China during the period of the disease’s first outbreak.

Methods

Study design

This was a cross-sectional observational study conducted in a non-ICU referral unit in Leishenshan Hospital, Wuhan, China, which is a designated newly established hospital to treat COVID-19 patients. This non-ICU referral unit was taken over by Shanghai General Hospital. The institutional ethics board of Shanghai General Hospital of Shanghai Jiao Tong University School of Medicine and Leishenshan Hospital approved this study. This ward received confirmed moderate and severe type of COVID-19 patients but not mild and critical cases, who were transferred from other hospitals. Diagnosis of COVID-19 was confirmed by nasopharyngeal or throat swab testing for SARS-CoV-2. The classification of COVID-19 patients and discharge criteria were according to the seventh edition of the COVID-19 diagnosis and treatment guideline of the National Health Commission of China. The classification criteria are as follows: mild type: clinical symptoms were mild and imaging showing no pneumonia; moderate type: have symptoms of fever, respiratory tract inflammation, and imaging showing pneumonia; severe type, meet any of the following criteria: dyspnea and respiratory rate ≥30 beats/min in the resting state, oxygen saturation ≤93% in the resting state, arterial blood oxygen partial pressure/ faction of inspired oxygen concentration ≤300 mmHg, lung imaging showed that the lesion progressed more than 50% within 24–48 h; Critical type, meet any of following criteria: respiratory failure requiring mechanical ventilation, shock, combined with other organs failure requiring ICU monitoring and treatment. Patients discharged must meet all the following criteria: body temperature returned to normal for more than 3 days, respiratory symptoms improved significantly, pulmonary imaging showed that the acute exudative lesions improved significantly, the SARS-CoV-2 nucleic acid test of respiratory tract samples was negative for two consecutive times (the sampling interval was more than 24 h).

In-patients who were consecutively admitted between 23 February 2020 and 5 April 2020 were included. If patients can’t offer specific information regarding the digestive symptoms, or had active GI diseases before COVID-19 onset, such as inflammatory bowel disease, peptic ulcer and gastroesophageal reflux disease, or suffered from active liver disease before COVID-19 onset, the cases were excluded. The enrolled patients were followed up until discharge.

The primary outcome is the prevalence of GI symptoms and elevation of liver enzymes throughout the disease’s course of COVID-19. The secondary outcome was to evaluate the correlation of GI symptoms and elevation of liver enzymes with disease classification and the disease duration.

Data collection

The relevant data was obtained from clinical medical charts and face-to-face interviews. Demographic and clinical data were collected from disease onset to discharge, which included gender; age; comorbidity histories (previous medical records, past drug history); smoking status; alcohol drinking;
date of disease onset; respiratory symptoms (cough, dyspnea); digestive symptoms (hyporexia/anorexia, nausea, vomiting, diarrhea, abdominal pain/discomfort); systemic symptoms (fever, fatigue); date of disease diagnosis; disease duration; laboratory test results (complete blood count, C-reactive protein, liver function, renal function, coagulation, etc.); chest CT scan; treatment measures. Diarrhea was defined as the passage of three or more stools per day, which meet the types 5–7 according to seven-item Bristol stool scale (16, 17). The disease duration was considered as the time from disease onset to discharge.

Statistical analysis

Continuous variables were expressed as mean ± standard deviation or median with the range in normally and abnormally distributed data. The differences between two groups were compared by Student’s t-test for normally distributed data or Wilcoxon rank sum test for abnormally distributed data. Categorical variables were expressed as frequency rates or percentages, and analyzed by chi-square test or Fisher’s exact test. In the multivariate analysis, stepwise logistic regression analysis or liner regression analysis was used. A two-tailed p-value <0.05 was considered statistically significant. All statistical analyses were conducted with SPSS software (version 19.0, IBM, Chicago, USA).

Results

Demographic and clinical characteristics of patients

A total of 95 consecutive patients were admitted to this ward during the study period. All patients can offer specific information regarding the whole disease course. Two of them who had active gastroesophageal reflux disease or peptic ulcer before COVID-19 onset were excluded. Finally, 93 patients (47 women and 46 men) were included in this study with an average age of 58.0 ± 12.1 years. The enrolled population had 42 (45.2%) moderate type patients and 51 (54.8%) severe type patients. During the study period, two severe type patients with GI symptoms were transferred to ICU for aggravation of illness, the other one had coronary heart disease. A large proportion of patients had at least one comorbidity (60.2%). The most frequent comorbidity was hypertension (39.8%), diabetes mellitus (15.1%), cardiac disease (8.6%), and cerebrovascular disease (8.6%). All patients were cured and discharged.

In our cohort, two patients presented anorexia as first symptom, one patient only showed anorexia without fever and respiratory symptoms, other patients developed GI symptoms at the same time of or after presenting fever or the respiratory symptoms, and 77 (82.8%) patients had respiratory symptoms including cough and dyspnea. Of enrolled patients, 65 patients (69.9%) showed at least one GI symptom, which presented as follows: 63 (67.7%) hyporexia/anorexia, 27 (29.0%) diarrhea, 26 (28.0%) nausea or vomiting, 20 (21.5%) abdominal discomfort/pain. If hyporexia/anorexia is excluded from GI symptoms because it is less specific for the GI tract, 46 (49.5%) patients showed at least one GI symptom. Twenty-two patients (23.7%) presented with abnormal liver function, including 22 patients with elevated ALT, 14 patients with elevated AST, and four patients with slightly elevated hemobilirubin. All abnormal liver function were found after the onset of COVID-19. Demographic and clinical parameters in patients were shown in Table 1. The details of patients are in the Supplementary material.

The relationship between GI symptoms or elevation of liver enzymes and clinical characteristics

Whether or not hyporexia/anorexia was included in GI symptoms, patients with GI symptoms have a significantly higher risk of severe type disease than patients without GI symptoms (67.7 vs. 25.0%, p < 0.001, including hyporexia/anorexia, Figure 1A; 71.7 vs. 38.3%, p = 0.001, not including hyporexia/anorexia). Compared with patients without GI symptoms, patients with GI symptoms showed a higher rate of shortness of breath (p < 0.001) and fatigue (p < 0.001), lower blood hemoglobin (p = 0.001) and albumin (p = 0.003), higher blood D-Dimer (p = 0.001) and urea nitrogen (p = 0.014), and longer disease duration (p = 0.026, Figure 1B). Patients with elevated liver enzymes showed a significantly higher risk of severe type disease (77.3 vs. 47.9%, p = 0.016, Figure 1A), fatigue (p = 0.041), glucocorticoid treatment (p = 0.007), lower albumin (p = 0.005), and longer disease duration (p = 0.046, Figure 1B). The results of the comparison in demographic, clinical and laboratory test parameters were shown in Tables 1, 2. In the subgroup analysis, hyporexia/anorexia, diarrhea and abdominal discomfort/pain were all associated with significantly higher risk of severe type disease (p < 0.00, p = 0.017, and p = 0.011, respectively). Patients with hyporexia/anorexia, diarrhea or nausea/vomiting have a higher risk of fatigue, and lower blood hemoglobin. Specific subgroup analysis data are shown in Table 3.

At multivariate analysis (including age, gender, comorbidities, hyporexia/anorexia, diarrhea, nausea/vomiting, abdominal discomfort/pain and elevation of liver enzymes), hyporexia/anorexia was confirmed as an independent predictive factor of severe type disease in the logistic regression analysis [odds ratio (OR): 5.912; 95% confidence interval (CI): 2.247–15.559; p < 0.001], and diarrhea was confirmed as an independent predictive factor of longer disease duration in
TABLE 1 Demographic and clinical parameters in patients with and without GI symptoms or elevated liver enzyme.

| Parameters       | Enrolled patients (n = 93) | GI symptoms | p-Value | Elevated liver enzyme | p-Value |
|------------------|----------------------------|-------------|---------|------------------------|---------|
|                  | With (n = 65)              | Without (n = 28) |          | With (n = 22)          | Without (n = 71) |
| Age, years       | 58.0±  12.1                | 58.7±  11.8  | 56.3± 13.0 | 0.397                  | 56.5± 12.6  | 58.4± 12.0  | 0.509 |
| Male             | 46                         | 30          | 16       | 0.331                  | 12        | 34          | 0.585 |
| Smoking          | 9                          | 5           | 4        | 0.324                  | 4         | 5           | 0.208 |
| Alcohol          | 5                          | 2           | 3        | 0.159                  | 2         | 3           | 0.589 |
| **Comorbidities**|                            |             |          |                        |           |             |       |
| None             | 37                         | 26          | 11       | 0.949                  | 9         | 28          | 0.902 |
| Any              | 56                         | 39          | 17       |                        | 13        | 43          |       |
| **Comorbidities**|                            |             |          |                        |           |             |       |
| HTN              | 37                         | 26          | 11       | 0.949                  | 9         | 28          | 0.902 |
| DM               | 14                         | 10          | 4        | 1.000                  | 1         | 13          | 0.175 |
| COPD             | 6                          | 3           | 3        | 0.361                  | 2         | 4           | 0.624 |
| Cardiac disease  | 8                          | 5           | 3        | 0.693                  | 2         | 6           | 1.000 |
| Cerebrovascular disease | 8          | 5           | 3        | 0.693                  | 0         | 8           | 0.191 |
| CKD              | 5                          | 5           | 0        | 0.131                  | 1         | 4           | 1.000 |
| CLD              | 6                          | 3           | 3        | 0.361                  | 1         | 5           | 1.000 |
| Malignancy       | 1                          | 0           | 1        | 0.301                  | 0         | 1           | 1.000 |
| **Symptoms**     |                            |             |          |                        |           |             |       |
| Fever            | 73                         | 52          | 21       | 0.590                  | 18        | 55          | 0.774 |
| Cough            | 70                         | 51          | 19       | 0.277                  | 18        | 52          | 0.415 |
| Shortness of breath | 53        | 45          | 8        | <0.001                 | 17        | 36          | 0.028 |
| Fatigue          | 59                         | 52          | 7        | <0.001                 | 18        | 41          | 0.041 |
| **Disease classification** |           |             |          |                        |           |             |       |
| Mild type        | 0                          | 0           | 0        | <0.001                 | 0         | 0           | 0.016 |
| Moderate type    | 42                         | 21          | 21       |                        | 5         | 37          |       |
| Severe (including critical type) | 51 (2) | 44 (2) | 7 (0) | 17 (1) | 34 (1) | |
| **Treatments**   |                            |             |          |                        |           |             |       |
| Antibiotics      | 35                         | 25          | 10       | 0.802                  | 11        | 24          | 0.171 |
| Antiviral        | 90                         | 63          | 27       | 1.000                  | 22        | 68          | 1.000 |
| Glucocorticoid   | 7                          | 6           | 1        | 0.670                  | 5         | 2           | 0.007 |
| Duration of disease, days | 54.3± 13.4 | 56.4± 12.7  | 49.6± 14.1 | 0.026                  | 59.3± 14.9| 52.8± 12.6  | 0.046 |

HTN, hypertension; DM, diabetes mellitus; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; CLD, chronic liver disease.

the liner regression analysis (p = 0.012). In addition, to study the relationship between GI symptoms or liver injury and other factors other than COVID-19, we included some factors (including age, gender, fever, comorbidities) for multivariate analysis. We found no significant correlation between these factors and GI symptoms or liver injury.
FIGURE 1
Comparison of percentage of severe type of disease (A) and disease duration (B) between patients with and without GI symptom/elevated liver enzymes. (*p < 0.05).

TABLE 2
Laboratory test in patients with and without GI symptoms or elevated liver enzyme.

| Parameters     | Enrolled patients (n = 93) | GI symptoms | p-Value | Elevated liver enzyme | p-Value |
|----------------|-----------------------------|-------------|---------|------------------------|---------|
|                | With (n = 65) | Without (n = 28) |         | With (n = 22) | Without (n = 71) |         |
| WBC, $\times 10^9$ cells/L | 6.1 (5.0, 7.4) | 6.0 (5.0, 7.4) | 6.1 (5.3, 7.5) | 0.471 | 6.8 (5.2, 8.2) | 5.9 (5.0, 7.0) | 0.071 |
| LYM, $\times 10^9$ cells/L | 1.4 (1.1, 1.8) | 1.4 (1.0, 1.7) | 1.5 (1.2, 1.8) | 0.188 | 1.4 (1.0, 1.8) | 1.4 (1.2, 1.8) | 0.735 |
| Neutrophil, $\times 10^9$ cells/L | 3.6 (2.7, 4.6) | 3.5 (2.7, 4.5) | 3.7 (2.8, 4.6) | 0.642 | 4.2 (3.4, 5.6) | 3.4 (2.6, 4.5) | 0.046 |
| HB, g/L | 118.0 (109.5, 128.0) | 116.0 (107.5, 124.5) | 126.5 (116.8, 137.5) | 0.001 | 118.0 (107.3, 126.8) | 118.0 (110.0, 128.0) | 0.769 |
| PLT, $\times 10^9$/L | 251.0 (202.5, 306.0) | 252.0 (203.0, 336.5) | 228.0 (192.5, 286.5) | 0.258 | 278.0 ± 112.4 | 253.5 ± 85.7 | 0.281 |
| CRP, mg/L | 1.9 (0.7, 7.1) | 1.9 (0.7, 7.3) | 2.1 (0.7, 4.7) | 0.615 | 2.0 (0.7, 7.3) | 1.9 (0.6, 6.6) | 0.618 |
| PT, s | 11.3 (11.0, 11.8) | 11.3 (10.9, 11.8) | 11.3 (11.0, 11.9) | 0.967 | 11.3 (11.0, 11.8) | 11.3 (11.0, 11.8) | 0.986 |
| APTT, s | 26.8 ± 4.2 | 26.7 ± 4.3 | 27.0 ± 3.9 | 0.795 | 26.9 ± 4.3 | 26.7 ± 4.2 | 0.853 |
| FL, g/L | 2.8 (2.4, 3.3) | 2.9 (2.5, 3.3) | 2.7 (2.3, 3.6) | 0.763 | 2.6 (2.3, 3.0) | 2.9 (2.5, 3.7) | 0.191 |
| D-dimer, mg/L | 0.5 (0.3, 1.1) | 0.7 (0.3, 1.2) | 0.3 (0.2, 0.6) | 0.001 | 0.8 (0.4, 1.1) | 0.5 (0.2, 1.0) | 0.123 |
| ALT, U/L | 30.0 (18.0, 47.0) | 30.0 (18.5, 63.0) | 29.5 (17.0, 36.5) | 0.243 | 65.5 (43.0, 150.5) | 24.0 (16.0, 35.0) | <0.001 |
| AST, U/L | 21.0 (16.5, 29.0) | 23.0 (16.5, 33.0) | 19.5 (16.3, 23.0) | 0.119 | 38.5 (23.5, 67.5) | 20.0 (16.0, 24.0) | <0.001 |
| TBIL, µmol/L | 10.2 (8.0, 14.8) | 10.3 (7.8, 15.0) | 10.2 (8.6, 13.0) | 1.000 | 11.5 (7.3, 15.6) | 10.0 (8.0, 13.2) | 0.684 |
| ALB, g/L | 37.9 (34.9, 39.5) | 37.7 (34.1, 38.5) | 38.8 (37.0, 41.2) | 0.003 | 36.3 (33.0, 38.0) | 38.1 (35.7, 40.1) | 0.005 |
| BUN, mmol/L | 5.2 (4.3, 6.4) | 5.5 (4.3, 6.7) | 4.9 (4.2, 5.3) | 0.014 | 5.5 (4.9, 6.6) | 5.0 (4.2, 6.4) | 0.204 |
| CR, µmol/L | 65.0 (55.4, 65.7) | 66.8 (54.7, 79.6) | 61.7 (55.5, 73.7) | 0.276 | 64.0 (53.6, 77.2) | 65.0 (55.2, 75.8) | 0.728 |
| UA, µmol/L | 324.3 ± 94.9 | 320.2 ± 95.0 | 333.9 ± 95.5 | 0.526 | 337.0 ± 111.6 | 320.4 ± 89.6 | 0.476 |

WBC, white blood cell; LYM, Lymphocyte; HB, hemoglobin; PLT, platelet; CRP, C-reactive protein; PT, prothrombin time; APTT, activated partial thromboplastin time; FL, fibrinogen; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBIL, total bilirubin; ALB, albumin; BUN, blood urea nitrogen; CR, creatinine; UA, uric acid.

Discussion

Patients with COVID-19 often present with respiratory symptoms, and can have GI symptoms and liver injury (14). However, there are few and inconsistent data on GI manifestations and liver injury in the early stage of the COVID-19 pandemic. Therefore, understanding the prevalence of GI symptoms and liver dysfunction and the relationship between GI symptoms or liver dysfunction and COVID-19 course in the early COVID-19 pandemic is helpful to investigate the variation of disease characteristics with virus mutation and measures for treating COVID-19.

This is an observational cross-sectional study conducted in a non-ICU referral unit in Wuhan during the course of the ...
TABLE 3 The subgroup analysis of patients with and without GI symptoms.

| Parameters | Hyporexia/anorexia | p-Value | Nausea/vomiting | p-Value | Diarrhea | p-Value |
|------------|-------------------|---------|-----------------|---------|----------|---------|
|            | With              | Without | With            | Without | With     | Without |
| Age, years | 59.0 ± 11.8       | 55.7 ± 12.7 | 55.6 ± 11.2     | 58.9 ± 12.4 | 0.225 | 0.249 | 57.6 ± 11.2 | 58.1 ± 12.6 | 0.854 |
| Male       | 30                | 16       | 0.606           | 12      | 34       | 0.691 | 10          | 36          | 0.125 |
| Fever      | 50                | 23       | 0.767           | 18      | 55       | 0.176 | 22          | 51          | 0.654 |
| Cough      | 49                | 21       | 0.416           | 20      | 50       | 0.818 | 22          | 48          | 0.374 |
| Shortness  | 44                | 9        | <0.001          | 18      | 35       | 0.137 | 20          | 33          | 0.033 |
| Fatigue    | 50                | 9        | <0.001          | 21      | 38       | 0.031 | 23          | 36          | 0.005 |
| Disease    |                   |          |                 |         |          |        |             |             | 0.017 |
| Mild type  | 0                 | 0        | 0               | 0       | 0        |       | 0           | 0           |       |
| Moderate type | 20             | 22       | 8               | 34      | 7        | 35    |             |             |       |
| Severe     | (including critical) type | 43 (2) | 8               | 18 (2)  | 33       | 20 (2) | 31          |             |       |

**Laboratory test**

| WBC count, ×10^9 cells per L | With | Without | p-Value |
|------------------------------|------|---------|---------|
| 6.0 (5.0, 7.3)               | 6.0 (4.9, 7.8) | 0.318 |

| LYM count, ×10^9 cells per L | With | Without | p-Value |
|------------------------------|------|---------|---------|
| 1.4 (1.0, 1.7)               | 1.5 (1.0, 1.7) | 0.141 |

| Neutrophil count, ×10^9 cells per L | With | Without | p-Value |
|-------------------------------------|------|---------|---------|
| 3.4 (2.7, 4.5)                     | 3.9 (3.0, 4.7) | 0.430 |

| HR, g/L | With | Without | p-Value |
|---------|------|---------|---------|
| 116.0 (108.0, 125.0)               | 123.5 (112.8, 136.5) | 0.004 |

| PLT, ×10^9/L | With | Without | p-Value |
|--------------|------|---------|---------|
| 253.0 (203.0, 339.0) | 228.0 (187.8, 283.5) | 0.155 |

| PT, s | With | Without | p-Value |
|-------|------|---------|---------|
| 11.3 (10.9, 11.8) | 11.3 (10.9, 11.8) | 0.961 |

| APTT, s | With | Without | p-Value |
|--------|------|---------|---------|
| 26.8 ± 4.4 | 26.8 ± 4.4 | 0.930 |

| FL, g/L | With | Without | p-Value |
|--------|------|---------|---------|
| 2.8 (2.4, 3.4) | 2.8 (2.5, 3.4) | 0.850 |

| D-dimer, mg/L | With | Without | p-Value |
|---------------|------|---------|---------|
| 0.8 (0.3, 1.3) | 0.3 (0.2, 0.6) | <0.001 |

| ALT, U/L | With | Without | p-Value |
|---------|------|---------|---------|
| 30.9 (19.0, 64.0) | 27.0 (16.3, 35.5) | 0.136 |

| AST, U/L | With | Without | p-Value |
|---------|------|---------|---------|
| 23.0 (17.0, 35.0) | 19.5 (16.0, 23.0) | 0.126 |

| TBIL, µmol/L | With | Without | p-Value |
|--------------|------|---------|---------|
| 10.3 (7.9, 14.8) | 10.2 (8.1, 13.8) | 0.987 |

| ALB, g/L | With | Without | p-Value |
|---------|------|---------|---------|
| 37.7 (33.9, 38.6) | 38.5 (36.7, 40.9) | 0.004 |

| Duration of disease, days | With | Without | p-Value |
|---------------------------|------|---------|---------|
| 56.7 ± 12.7               | 56.1 ± 12.0 | 0.015 |

WBC, white blood cell; LYM, lymphocyte; HR, Hemoglobin; PLT, platelet; PT, prothrombin time; APTT, activated partial thromboplastin time; FL, fibrinogen; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBIL, total bilirubin; ALB, albumin.

COVID-19 first outbreak. We investigated the GI symptoms and liver injury throughout the COVID-19 course. We found that 69.9% patients showed at least one GI symptom, and 23.7% patients experienced elevation of liver enzymes. The most common GI symptoms were hyporexia/anorexia, followed by diarrhea, nausea/vomiting and abdominal discomfort/pain.
Even if hyporexia/anorexia was excluded from GI symptoms for less specific to the GI tract, about half of the patients presented at least one GI symptom. The manifestations of GI symptoms are similar to published reports. However, the prevalence of GI symptoms and liver enzyme elevation in our study is higher than some published studies in the early COVID-19 pandemic (2, 18, 19). The difference between our results and published reports may be partly related to the different attention to GI symptoms among the clinicians. Moreover, we investigate GI symptoms and liver enzyme in the whole course of disease, but most published studies focus on the GI symptoms and liver enzyme only at admission which could cause underestimating the prevalence. So, this study can offer results closer to the actual situation. As the pandemic spread, comparative analysis by patient location showed a significantly higher proportion of GI symptom and abnormal liver enzymes in the non-China subgroup (6). At present, there is a lack of detailed information of GI symptom and liver injury at patients infected with different virus variants, such as Omicron or Delta variants. Further investigation is needed to study if the virus mutation as spread might affect its tropism for the digestive tract and liver.

Published studies about the relationship between GI symptoms or elevation of liver enzymes and clinical characteristics came to inconsistent results in the early COVID-19 pandemic. Several reports showed that COVID-19 patients with GI symptoms or elevation of liver enzymes were severer with higher ICU admission (8, 10, 14, 15). Conversely, some studies considered that COVID-19 patients with GI symptoms have less lung involvement and better prognosis (4, 11, 12). In our study, we found that COVID-19 patients with GI symptoms or elevation of liver enzymes experienced severer clinical course, with a higher rate of severe type of disease, lower blood hemoglobin and albumin, and longer disease duration. Furthermore, hyporexia/anorexia was an independent predictive factor of severe type disease, and diarrhea was an independent predictive factor of longer disease duration. GI symptoms can affect the intake and absorption of nutrients, which is related to low hemoglobin and albumin. Liver dysfunction can complicate the disease. These factors can aggravate the COVID-19. The cause of GI symptoms or elevation of liver enzymes is not clear at present. Hyporexia/anorexia may be part of the systemic inflammatory response, which is involved in the action of cytokines and microbial products on the central nervous system (20). SARS-CoV-2 could infect cells through the angiotensin-converting enzyme 2 receptor, expressed in the GI tract and liver cells (21, 22). The mechanisms of GI symptoms and liver injury may include direct infection of SARS-CoV-2, side effects of drugs, gut microbiota disorder and inflammatory immune response (23–25). Therefore, understanding of these mechanisms could help us to better manage those patients with GI symptoms and liver injury.

There are some limitations in our study. Firstly, our cohort mainly included only moderate and severe types of patients in a non-ICU ward who were relatively old and often had comorbidities, and can’t represent all COVID-19 patients. However, even if mild type of patients is included, the occurrence of GI symptoms is also common in some reports (26). Secondly, this study did not differentiate the GI symptoms and liver injury at different stages of the disease. Finally, this study enrolled a relatively small sample size, and carried out at a hospital which only received patients transferred from other hospitals. So, a selection bias in the COVID-19 population is inevitable.

Our study design also presents strengths. We focus on GI symptoms and liver injury in a group of patients in Wuhan during the course of the disease's first outbreak, which lacked in-depth investigation. And we carried out a cross-sectional observational study, which can increase information accuracy compared with retrospective study. Moreover, we have investigated the incidence of GI symptoms and liver enzyme elevation throughout the course of the COVID-19. In contrast, many published studies have only reported the occurrence at or before admission.

In conclusion, this cross-sectional observational study presented results closer to the actual situation in the early stage of COVID-19 pandemic. It showed that GI symptoms and elevated liver enzymes are common throughout the disease course, and associated with severer disease and longer disease duration.

Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary material.

Ethics statement

The studies involving human participants were reviewed and approved by the Institutional Ethics Board of Shanghai General Hospital of Shanghai Jiao Tong University School of Medicine and Leishenshan Hospital. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

Author contributions

DC and JL: design of the study and editing the article. DC, YF, and MN: acquisition of data and statistical analysis. DC and MN: drafting the article. All authors contributed to the article and approved the submitted version.
Conflicts of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2022.997000/full#supplementary-material

References

1. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus-classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. (2020) 5:336–44. doi: 10.1038/s41564-020-0369-z
2. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He QX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. (2020) 382:1708–20. doi: 10.1056/NEJMoa2002032
3. Ferm S, Fisher C, Pakala T, Tong M, Shah D, Schwarzbaum D, et al. Analysis of gastrointestinal and hepatic manifestations of SARS-CoV-2 infection in 892 patients in Queens, NY. Clin Gastroenterol Hepatol. (2020) 18:2378–9. doi: 10.1016/j.cgh.2020.05.049
4. Schettino M, Pellegrini L, Picascia D, Saibeni S, Bezzio C, Bini F, et al. Clinical characteristics of COVID-19 patients with gastrointestinal symptoms in Northern Italy: a single-center cohort study. Am J Gastroenterol. (2021) 116:396–10. doi: 10.14309/ajg.0000000000000965
5. Miao R, Qiu Y, He JS, Tan JY Li XH, Liang J, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. (2020) 5:667–78. doi: 10.1016/S2582-1257(20)30126-6
6. Sultan S, Altayar O, Siddique SM, Davitkov P, Feuerstein JD, Lim JK, et al. Gastrointestinal Infection of SARS-CoV-2. Clin Gastroenterol Hepatol. (2020) 18:3032–34. doi: 10.1016/j.cgh.2020.05.001
7. Ma C, Cong Y, Zhang H. COVID-19 and the digestive system. Am J Gastroenterol. (2020) 115:1003–6. doi: 10.14309/ajg.0000000000000691
8. Wan Y, Li J, Shen L, Zou Y, Hou L, Zha L, et al. Enteric involvement in hospitalized patients with COVID-19 outside Wuhan. Lancet Gastroenterol Hepatol. (2020) 5:534–5. doi: 10.1016/S2582-1257(20)30118-7
9. Pan L, Mu M, Yang P, Sun Y, Wang R, Yan J, et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterol. (2020) 115:766–73. doi: 10.14309/ajg.0000000000000620
10. Jin X, Lian JS, Hu JH, Gao J, Zheng L, Zham YM, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut. (2020) 69:1002–9. doi: 10.1136/gutjnl-2020-329262
11. Buscarini E, Manfredi G, Brambilla G, Menozzi F, Londoni C, Alicante S, et al. GI symptoms as early signs of COVID-19 in hospitalised Italian patients. Gut. (2020) 69:1547–8. doi: 10.1136/gutjnl-2020-321434
12. Ramachandran P, Onulogu I, Ghanta S, Gajendran M, Periassi A, Goyal H, et al. Gastrointestinal symptoms and outcomes in hospitalized coronavirus disease 2019 patients. Dig Dis. (2020) 38:373–9. doi: 10.1159/000509774
13. Cichock-Lach H, Michalak A. Liver injury in the era of COVID-19. World J Gastroenterol. (2021) 27:377–90. doi: 10.3748/wjg.v27.i5.377
14. Shehab M, Alrashed F, Shuaibi S, Alajmi D, Barkun A. Gastroenterological and hepatic manifestations of patients with COVID-19, prevalence, mortality by country, and intensive care admission rate: systematic review and meta-analysis. BMJ Open Gastroenterol. (2021) 8:e000571. doi: 10.1136/bmjgast-2020-000571
15. Hundt MA, Deng Y, Carleglio MM, Nathanson MH, Lim JK. Abnormal liver tests in COVID-19: a retrospective observational cohort study of 1,827 patients in a major US Hospital Network. Hepatology. (2020) 72:1169–76. doi: 10.1002/hep.31487
16. Reintam Blaser A, Duane AM, Fruhwald S. Diarrhoea in the critically ill. Curr Opin Crit Care. (2021) 27:142–53. doi: 10.1097/MCC.0000000000001188
17. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. (1997) 32:920–4. doi: 10.3109/00365529709121203
18. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. (2020) 395:507–13. doi: 10.1016/S0140-6736(20)30211-7
19. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. (2020) 395:497–506. doi: 10.1016/S0140-6736(20)30183-5
20. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. (2020) 395:1033–4. doi: 10.1016/S0140-6736(20)30268-0
21. Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for Gastrointestinal Infection of SARS-CoV-2. Gastroenterology. (2020) 158:1831–3. doi: 10.1053/j.gastro.2020.02.055
22. Hamming I, Timens W, Bulbuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. (2004) 203:631–7. doi: 10.1082/path.1570
23. Zuo T, Zhang F, Liu GY, Yeoh YK, Li AYL, Zhan H, et al. Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. Gastroenterology. (2020) 159:944–55.e8. doi: 10.1053/j.gastro.2020.05.048
24. Lei HY, Ding YH, Nie K, Dong YM, Xu JH, Yang ML, et al. Potential effects of SARS-CoV-2 on the gastrointestinal tract and liver. Biomed Pharmacother. (2021) 133:111064. doi: 10.1016/j.biopha.2020.11.1064
25. Zhong P, Xu J, Deng D, Shen Y, Wang L, Feng Y, et al. COVID-19-associated gastrointestinal and liver injury: clinical features and potential mechanisms. Signal Transduct Target Ther. (2020) 5:256. doi: 10.1038/s41392-020-00373-7
26. Andrews PLR, Cai W, Rudd JA, Sanger GJ. COVID-19, nausea, and vomiting. J Gastroenterol Hepatol. (2021) 36:646–56. doi: 10.1111/jgh.15261